Carlos Arteaga

Carlos Arteaga at UT Southwestern has made foundational contributions to understanding HER2 biology, trastuzumab mechanisms of action and resistance, and the development of lapatinib and neratinib as targeted therapies in HER2-positive breast cancer. His laboratory established that PI3K pathway activation is a key mechanism of trastuzumab resistance, providing the rationale for combination strategies. He has contributed to the development of neratinib as an irreversible pan-HER inhibitor and has evaluated multiple combination strategies to overcome HER2 inhibitor resistance. His career-long dedication to HER2 biology and targeted therapy has produced dozens of contributions that have shaped the field.